|
Market Closed -
Nasdaq
01:30:00 14/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 31.34 USD | -0.25% |
|
+5.06% | +1.75% |
| 12/08 | BNP Paribas Initiates Genmab at Outperform, With $40 Price Target | MT |
| 12/08 | Nordic stocks in North America: AstraZeneca fell 1.0% | FW |
Company Valuation: Genmab A/S
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,72,063 | 1,92,229 | 1,40,770 | 94,810 | 1,24,862 | 1,20,896 | - | - |
| Change | - | 11.72% | -26.77% | -32.65% | 31.7% | -3.18% | - | - |
| Enterprise Value (EV) 1 | 1,52,725 | 1,69,905 | 1,12,635 | 73,709 | 1,14,029 | 1,40,516 | 1,32,025 | 1,19,319 |
| Change | - | 11.25% | -33.71% | -34.56% | 54.7% | 23.23% | -6.04% | -9.62% |
| P/E | 57.8x | 35.2x | 32.6x | 12.3x | 20.9x | 25.6x | 18x | 12x |
| PBR | 7.82x | 7.07x | 4.5x | 2.68x | 3.47x | 3.05x | 2.58x | 2.14x |
| PEG | - | 0.4x | -1.5x | 0.1x | -1x | -1.4x | 0.4x | 0.2x |
| Capitalization / Revenue | 20.3x | 13.2x | 8.54x | 4.4x | 5.31x | 4.17x | 3.59x | 2.97x |
| EV / Revenue | 18x | 11.6x | 6.84x | 3.42x | 4.85x | 4.84x | 3.92x | 2.93x |
| EV / EBITDA | 46.8x | 25.3x | 20.1x | 10.4x | 15.9x | 16.3x | 10.8x | 7.06x |
| EV / EBIT | 50.6x | 26.7x | 21.2x | 10.5x | 17x | 18.3x | 13x | 8.37x |
| EV / FCF | 77.3x | 47.3x | 16.1x | 9.72x | 15.7x | 26.1x | 15.2x | 8.41x |
| FCF Yield | 1.29% | 2.12% | 6.23% | 10.3% | 6.36% | 3.83% | 6.57% | 11.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 45.54 | 83.65 | 66.02 | 121.4 | 97.08 | 79.2 | 112.7 | 168.2 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8,482 | 14,595 | 16,474 | 21,526 | 23,497 | 29,011 | 33,710 | 40,668 |
| EBITDA 1 | 3,266 | 6,719 | 5,616 | 7,116 | 7,175 | 8,645 | 12,169 | 16,907 |
| EBIT 1 | 3,018 | 6,357 | 5,321 | 7,003 | 6,727 | 7,687 | 10,139 | 14,248 |
| Net income 1 | 3,008 | 5,522 | 4,352 | 7,844 | 6,083 | 4,941 | 7,173 | 10,682 |
| Net Debt 1 | -19,338 | -22,324 | -28,135 | -21,101 | -10,833 | 19,620 | 11,129 | -1,577 |
| Reference price 2 | 2,630.00 | 2,941.00 | 2,155.00 | 1,492.50 | 2,027.00 | 2,025.00 | 2,025.00 | 2,025.00 |
| Nbr of stocks (in thousands) | 65,423 | 65,362 | 65,322 | 63,524 | 61,599 | 59,702 | - | - |
| Announcement Date | 16/02/22 | 22/02/23 | 14/02/24 | 12/02/25 | 17/02/26 | - | - | - |
1DKK in Million2DKK
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.94x | 7.34x | 14.96x | 1.38% | 7.01TCr | |
| 31.3x | 7.97x | 24.33x | 0.05% | 5.49TCr | |
| -86.53x | 15.66x | -79.82x | -.--% | 2.89TCr | |
| 30.32x | 5.94x | 15.72x | -.--% | 2.39TCr | |
| -14.59x | 5.14x | -6.7x | -.--% | 2.33TCr | |
| 25.72x | 4.87x | 16.34x | -.--% | 1.88TCr | |
| 55.29x | 22.62x | 58.25x | 0.07% | 1.84TCr | |
| -1224.8x | 38.27x | -15166.74x | -.--% | 1.61TCr | |
| 15.63x | 4.6x | 10.74x | -.--% | 1.25TCr | |
| Average | -127.41x | 12.49x | -1,679.21x | 0.17% | 2.97TCr | |
| Weighted average by Cap. | -63.51x | 10.67x | -908.05x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Valuation Genmab A/S
Select your edition
All financial news and data tailored to specific country editions
